

Statin Treatments And Dosages In Children With Familial Hypercholesterolemia: Meta-Analysis

Graciane Radaelli,¹ Grasiele Sausen,¹ Claudia Ciceri Cesa,¹ Francisco de Souza Santos,² Vera Lucia Portal,¹ Jeruza Lavanholi Neyeloff,¹ Lucia Campos Pellanda¹ Instituto de Cardiologia - Fundação Universitária de Cardiologia – IC/FUC,¹ Porto Alegre, RS – Brazil Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS),² Porto Alegre, RS – Brazil

Abstract

Background: Children with familial hypercholesterolemia may develop early endothelial damage leading to a high risk for the development of cardiovascular disease (CVD). Statins have been shown to be effective in lowering LDL cholesterol levels and cardiovascular events in adults. The effect of statin treatment in the pediatric population is not clearly demonstrated.

Objective: To systematically review the literature to evaluate the effects of different statins and dosages in total cholesterol levels in children and adolescents with familial hypercholesterolemia. We also aimed to evaluate statin safety in this group.

Methods: PubMed, EMBASE, Bireme, Web of Science, Cochrane Library, SciELO and LILACS databases, were searched for articles published from inception until February 2016. Two independent reviewers performed the quality assessment of the included studies. We performed a meta-analysis with random effects and inverse variance, and subgroup analyses were performed.

Results: Ten trials involving a total of 1543 patients met the inclusion criteria. Our study showed reductions in cholesterol levels according to the intensity of statin doses (high, intermediate and low): (-104.61 mg/dl, -67.60 mg/dl, -56.96 mg/dl) and in the low-density lipoprotein cholesterol level: [-105.03 mg/dl (95% Cl -115.76, -94.30), l2 19.2%], [-67.85 mg/dl (95% Cl -83.36, -52.35), l2 99.8%], [-58.97 mg/dl (95% Cl -67.83, -50.11), l2 93.8%. The duration of statin therapy in the studies ranged from 8 to 104 weeks, precluding conclusions about long-term effects.

Conclusion: Statin treatment is efficient in lowering lipids in children with FH. There is need of large, long-term and randomized controlled trials to establish the long-term safety of statins. (Arq Bras Cardiol. 2018; 111(6):810-821)

Keywords: Statins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia Type II/genetic; Children; Meta-Analysis.

Introduction

Familial hypercholesterolemia (FH) is a dominant autosomal genetic disease. The worldwide prevalence is of 1 in 250 people affected with the heterozygous form (HeFH) of HF.¹ FH is characterized by high levels of low-density lipoprotein (LDL) cholesterol due the reduced hepatic capacity to remove LDL-cholesterol from blood circulation,² which can result in early atherosclerosis development.³ Further, children with FH have damage in the endothelial function and increased intima-media thickness (IMT)⁴ indicating early atherogenesis.

The hydroxy-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors or statins decrease the coronary morbidity and mortality in high-risk adults. They have proven to be effective in decreasing LDL-cholesterol levels and cardiovascular events in adults.⁵ Statins are one of the most prescribed drugs in the world⁶ for adults and, in usual doses, are notably safe.

Mailing Address: Lucia Campos Pellanda •

Av. Princesa Isabel, 370, 3º andar. Postal Code 99620-000, Santana, Porto Alegre, RS – Brazil

E-mail: pellanda.pesquisa@gmail.com, metodologia.up@cardiologia.org.br Manuscript received February 20, 2018, revised manuscript May 15, 2018, accepted June 27, 2018

DOI: 10.5935/abc.20180180

The expert consensus recommends drug treatment for children older than 10 years old with LDL-cholesterol level $\geq 5 \text{ mmol/L}$ (190 mg/dl), whose cholesterol levels remain elevated despite diet measures during the period from 8 weeks to 2 years for children ages 8–18 years. It is also considered the treatment for those with LDL-cholesterol $\geq 4 \text{ mmol/L}$ (160 mg/dl) with the presence of two or more cardiovascular risk factors or family history of CVD.^{2,7}

The US Food and Drug Administration (FDA)⁸ has approved the use of some statins like simvastatin, atorvastatin, fluvastatin, pravastatin, rosuvastatin and lovastatin for pediatric and adolescent patients. Pravastatin is approved for use at 8 years of age, other statins are approved for use from 10 years on. FDA⁸ recommends statins for children with FH, primary or genetic dyslipidemia. The treatment to reduce cholesterol levels in pediatric patients is based on evidence involving only adults.⁹ The effect of statins in pediatric population has been limited to short-term randomized clinical trials (RCTs).^{10,11}

Thus, the aim of this study was to systematically review the literature to evaluate the effects of different statins and the dosages in elevated plasma levels of total cholesterol (TC), LDL- cholesterol and apolipoprotein B (APOB) and in decreased high-density lipoprotein (HDL) cholesterol levels in children and adolescents with FH. We also aimed to evaluate statin safety in this group.

Methods

A systematic review was conducted according to Cochrane Collaboration and Preferred Reporting Items for Systematic Review and Meta-analyses: the PRISMA Statement.¹²

Eligibility criteria

Studies included RCTs performed in children and adolescents from 8 to 18 years old, submitted to statin therapy for treatment of familial hypercholesterolemia. The intervention was considered as the use of statins at any dose, for at least eight weeks. Our protocol has assessed increased plasma levels of TC, LDL-cholesterol and APOB, and decreased HDL-cholesterol, in addition to seeking evidence on the effectiveness, safety and effects of statins. The RCTs were included if fulfilled the inclusion criteria and had at least one primary or secondary outcome. Studies that did not provide information on the magnitude of the intervention's effect in the control or experimental groups were excluded. When a study had several publications (or sub-studies), only the most recent was included. The other publications were used to supplement information.

Information sources

The review protocol was registered in the International Register of Prospective Systematic Reviews (PROSPERO), under registration number: CRD42015029350. The search comprised seven online databases - PubMed, EMBASE, Bireme, Web of Science, Cochrane Library, SciELO and LILACS. It lasted from the beginning to February 2016 and was composed by entries related to the following terms: "child", "adolescents", "cholesterol", "hypercholesterolemia", "statins", "dyslipidemia", "inhibitor hidroximethylglutaril-CoA reductase". There was no language restriction and we adopted a high-sensitivity strategy for the search of randomized controlled trials.13 To identify other primary studies, the authors searched and checked for reference lists of previously published systematic reviews and meta-analyses. The detailed strategies for PubMed are in Appendix I. The strategies for other databases are available upon request.

Study selection and data extraction

Two investigators (G.R. and G.S.), in duplicate and independently, evaluated the titles and abstracts of all articles identified by the search strategy. The abstracts that provide enough information regarding the inclusion and exclusion criteria were selected for full-text evaluation. In the second phase, the same reviewers independently evaluated the full text of these articles and made their selection in accordance with the eligibility criteria. Disagreements between reviewers were solved by consensus, and when disagreement persisted it was solved by a third reviewer (L.C.P.). These two reviewers (G.R. and G.S.) independently conducted data extraction regarding the methodological characteristics of the studies, interventions and outcomes using standardized forms. The CONSORT analysis instrument was used to evaluate methodological quality (internal and external validation) of the included clinical trials. The outcomes extracted in this meta-analysis were: TC (mg/dl), LDL-C (mg/dl), HDL-C (mg/dl), APOB (mg/dl).

Assessment of risk of bias

Quality assessment of studies included adequate sequence generation, adequate allocation concealment, blinding of investigator, participants, and outcomes assessors, intention-to-treat analysis and description of losses and exclusions. Studies had to have a clear description of an adequate sequence generation to fulfill these criteria. The description of how the allocation list was concealed could include terms like "central", "web-base" or "telephone randomization" or computer-generation.

Intention-to-treat analysis was considered as confirmation on study assessment that the number of participants randomized and the number analyzed were identical, except for patient lost to follow-up or those who withdrew consent for study participation. Two reviewers independently performed quality assessment, and, for each criterion, studies were classified as adequate, not adequate or unclear/not reported.

Data Synthesis and Statistical Analysis

All analyses were conducted using Software RStudio.14 For continuous outcomes, if the unit of measurement was consistent throughout trials, results were presented as weighted mean difference with 95% of confidence intervals (CIs). Calculations were performed using random effects method and the statistical method used was inverse variance. Statistical significance defined for the analyzes as p < 0.05. Statistical heterogeneity of the treatment effects among studies was assessed using Cochran's Q test and the inconsistency I² test. In addition, sensitivity analysis of RCTs was performed to assess differences in the intervention approach (intervention group versus placebo). In studies where statins therapy compared three different arms of treatment (intervention group) versus placebo (control group), we will conduct weighted average and divide the total number of patients to the distribution of the control group.¹⁵

Results

Description of studies

We initially identified 16793 potentially relevant citations from electronic databases. A total of 15 RCTs were included in the synthesis of qualitative studies and10 RCTs^{10,11,16-23} were selected to the quantitative analysis. Studies that were not eligible for the quantitative analysis did not provided data on cholesterol levels²⁴⁻²⁷ in a way that we could extract them from the article, and one study²⁸ was not performed with a control group. Figure 1 shows the summary of evidence search and study selection in this review. The included studies comprised a total of 1543 subjects, and they were all full peer-reviewed publications.

Participants

Table1 summarizes the characteristics of participants and included studies. The number of participants in the studies ranged from 54 to 248. A total of 934 subjects received statin therapy and 609 received placebo. The age also varied from 8 to 18 years old. The studies have evaluated different types of statins for a period of 8 to 104 weeks.

Radaelli et al Statin treatment in children: meta-analysis

Original Article



Figure 1 – Summary of evidence search and study selection.

Risk of bias in included studies

Allocation

Generation of sequence

The generation of the allocation sequence was adequate in two studies since the sequence was computer-generated.^{10,18} The remaining ten studies were described as randomized, but no further details of the process were given (Table 2).

Concealment of allocation

None of the included studies described how the allocation sequence was concealed from the investigators, the outcome assessors or the participants in the study (Table 2).

Blinding

All studies were described as double blind, indicating that participants and those participating in treatment procedures were blinded to treatment (Table 2).

Incomplete outcome data

From the studies included, 90% reported intention-to-treat analyses and 80% described losses due to follow-up and exclusions.

Effects of interventions

Statins versus placebo

All included studies describe the use of therapy with statins: atorvastatin,¹⁶ lovastatin,^{10,21} pravastatin,^{17,18,19} rosuvastatin,²⁰ simvastatin^{11,22} and pitavastatin.²³ The dosage and duration of treatment with statins varied between them (Table 1). The detailed analyzes are in Appendix II, III, IV, and V.

Change in Total cholesterol

Ten of the included studies evaluated the effect of statin therapy on the TC level.^{10,11,16-23} A subgroup analysis was performed in line with the intensity of statin doses, classified according to expected LDL-cholesterol reduction effect²⁹: \leq 30% as low; 30–40%, intermediate, and \geq 40%, high.

Study, year	Randomized patients (n) intervention/placebo	Participants Age range	Intervention group	Control group	Duration of intervention	Statistical significance	Evaluated outcomes
Knipscheer et al., 1996	54/18	8 to 16 years	Pravastatin: (1) 5 mg/day, (2) 10 mg/day, and (3) 20 mg/day	Placebo	12 weeks	p < 0.05	TC, LDL-C, TGs, HDL-C, apo A-I, apo B, Lp(a), VLDL-C, ALT, AST, hormones
Stein et al., 1999	67/65	10 to 17 years	Lovastatin 10 mg/day for 8 weeks; 20 mg/d for 8 weeks, 40 mg/day	Placebo	48 weeks	p < 0.05	LDL-C, TGs, TC, HDL-C, apo A-I, apo A-II, apo B, Lp(a), testicular volume, ALT, AST, hormones, growth and development
de Jongh et al., 2002	106/69	10 to 17 years	Sinvastatin 10 mg/day for 8 weeks; 20 mg/day for 8 weeks; 40 mg/day	Placebo	48 weeks	p < 0.05	LDL-C, CT, TGs, HDL-C, apo A-I, apo B, VLDL-C, hsCRP, ALT, AST, homones
McCrindle et al., 2003	140/47	10 to 17 years	Atorvastatin 10 mg/day; 20 mg/day if LDL \geq 3.4 at weeks 4	Placebo	26 weeks	p < 0.05	LDL-C, CT, TGs, HDL-C, apo A-I, apo B, ALT, AST, homones
Wiegman et al., 2004	106/108	8 to 18 years	Pravastatin 20 mg/day if <14 years of age; 40 mg/day if ≥ 14 years of age	Placebo	104 weeks	p < 0.05	LDL-C, TGs, TC, HDL-C, Lp(a), carotid IMT, growth, maturation, hormone level, liver and muscle enzymes
Clauss et al., 2005	35/19	10 to 17 years	Lovastatin 20 mg/day for 4 weeks; 40 mg/day	Placebo	24 weeks	p ≤ 0.05	LDL-C, TGs, HDL-C, apo A-I, apo B, Lp(a), VLDL-C, ALT, AST, hormones
Rodenburg et al., 2006	88/06	8 to 8 years	Pravastatin 20 mg/day if <14 years of age; 40 mg/day if ≥ 14 years of age	Placebo	104 weeks	p < 0.05	LDL-C, TC, TGs, HDL-C, apo B, Lp(a), VLDL-C, carotid IMT, C-reactive protein, OxLDL markers, Immune complexes
	intervention/placebo	Age range			intervention		outcomes
Van der Graaf et al. 2008	126/122	10 to 17 years	Simvastatin: (1) 10 mg/day, 20 mg/day, or 40 mg/day plus azetimibe 10 mg/day or placebo for 6 weeks; Sinvastatin: (2) 40 mg/day plus azetimibe 10 mg/day or placebo for 27 weeks; All subjects received open-label: (3) simvastatin 10 mg/day or 20 mg/day plus azetimibe 10 mg/day for 20 weeks;	Placebo	53 weeks	p < 0.05	LDL-C, TC, TGs, HDL-C, apo B
Avis et al., 2010	131/46	10 to 17 years	Rosuvastatin: 5 mg/day, 10 mg/day, 20mg/day	Placebo	12 weeks	p < 0.05	ALT, AST, CK, GFR, urine, TC, LDL-C, TGs, HDL-C, apo A-I, apoB
	79/27	6 to 17 years	Pitavastatin: 1 mg/day, 2 mg/day, 4 mg/day	Placebo	12 weeks	p < 0.05	TC, LDL-C, HDL-C, TGs, apo A-I, apoB

Knipscheer et al., 1996Not reportedUnclearNot reportedNoStein et al., 1999Not reportedUnclearNot reportedNode Jongh et al., 2002Not reportedUnclearNot reportedNoMcCrindle et al., 2003Not reportedUnclearNot reportedNoWriegman et al., 2004YesUnclearNot reportedNoKodenburg et al., 2005YesAdequateNot reportedNoRodenburg et al., 2006Not reportedUnclearNot reportedNoRodenburg et al., 2008Not reportedUnclearNot reportedNo	reported Unclear Not reported		assessors	analysis ^b	and exclusions
Stein et al., 1999Not reportedUnclearNot reportedNode Jongh et al., 2002Not reportedUnclearNot reportedNoMcCrindle et al., 2003Not reportedUnclearNot reportedNoWiegman et al., 2004YesUnclearNot reportedNoClauss et al., 2005YesAdequateNot reportedNoRodenburg et al., 2006Not reportedUnclearNot reportedNoRodenburg et al., 2006Not reportedUnclearNot reportedNoVan der Graaf et al. 2008Not reportedUnclearNot reportedNo		Not reported	Not reported	Yes	No
de Jongh et al., 2002 Not reported Unclear Not reported No McCrindle et al., 2003 Not reported Unclear Not reported No Wiegman et al., 2004 Yes Unclear Not reported No Clauss et al., 2005 Yes Adequate Not reported No Rodenburg et al., 2006 Not reported Unclear Not reported No Rodenburg et al., 2008 Not reported Unclear Not reported No Van der Graaf et al. 2008 Not reported Unclear Not reported No	reported Unclear Ivot reported	Not reported	Not reported	Yes	Yes
McCrindle et al., 2003 Not reported Unclear Not reported No Wiegman et al., 2004 Yes Unclear Not reported No Kiegman et al., 2005 Yes Adequate Not reported No Rodenburg et al., 2006 Not reported Unclear Not reported No Rodenburg et al., 2006 Not reported Unclear Not reported No Van der Graaf et al. 2008 Not reported Unclear Not reported No	reported Unclear Not reported	Not reported	Not reported	Yes	Yes
Wiegman et al., 2004 Yes Unclear Not reported No Clauss et al., 2005 Yes Adequate Not reported No Rodenburg et al., 2006 Not reported Unclear Not reported No Van der Graaf et al. 2008 Not reported Unclear Not reported No	reported Unclear Not reported	Not reported	Not reported	Yes	Yes
Clauss et al., 2005 Yes Adequate Not reported No Rodenburg et al., 2006 Not reported Unclear Not reported No Van der Graaf et al. 2008 Not reported Unclear Not reported No	Yes Unclear Not reported	Not reported	Not reported	No	Yes
Rodenburg et al., 2006 Not reported Unclear Not No Van der Graaf et al. 2008 Not reported Unclear No No	Yes Adequate Not reported	Not reported	Not reported	Yes	Yes
Van der Graaf et al. 2008 Not reported Unclear Not reported No	reported Unclear Not reported	Not reported	Not reported	Yes	No
	reported Unclear Not reported	Not reported	Not reported	Yes	Yes
Avis et al., 2010 Not reported Unclear Not reported No	reported Unclear Not reported	Not reported	Not reported	Yes	Yes
Braamskamp et al., 2015 Not reported Unclear Not reported No	reported Unclear Not reported	Not reported	Not reported	Yes	Yes

In this analysis, all subgroups maintained significant reductions in cholesterol levels (-104.61 mg/dl, -67.60 mg/dl, -56.96 mg/dl), and intragroup heterogeneity was lower (18%, 99.7%, 95.4%). This analysis explained 99.4% of the original heterogeneity found in the main analysis (Figure 2).

Change in LDL-cholesterol level

Ten included studies evaluated the effect of statin therapy on the LDL-cholesterol level.^{10,11,16-23} All subgroup analysis demonstrated significant reduction in this level: [-105.03 mg/ dl (95% CI -115.76, -94.30), l² 19.2%], [-67.85 mg/dl (95% CI -83.36, -52.35), l² 99.8%], [-58.97 mg/dl (95% CI -67.83, -50.11), l² 93.8%], (Figure 3). The detailed analyzes are in Appendices II, III, IV, and V.

Discussion

no evidence of intention-to-treat confirmed by our analysis)

We quantitatively analyzed ten randomized placebocontrolled trials in children with FH. Studies showed a clinically significant reduction in LDL-cholesterol levels in children treated with statin, compared to those treated with placebo. In addition, therapy with statins slightly increased HDL-cholesterol. The reduction in LDL-cholesterol levels varied between studies, probably due to different statins and dosages, and, possibly due to different settings of HeFH.

In our meta-analysis, the results of all studies using statins were combined. All statins included present a common mechanism of action, i.e., inhibition of hydroxy-methyl-glutary-Coa. All statins have shown beneficial effects in lowering lipid levels and have been approved for use in adult patients with dyslipidemia.

When comparing some results: the study using lovastatin to evaluate efficacy and safety in children, focusing on female population, concluded that the lovastatin group showed a reduction in LDL-cholesterol levels of 23% to 27% against an increase of 5% in the placebo group (p < 0.001), TC of 17% to 22%, and APOB of 20% to 23%.¹⁰ Whereas another study with young male patients,²¹ lasting 24 weeks, lovastatin significantly reduced LDL-cholesterol levels at all dosages compared with placebo (17%, 24%, 27% with dosage of 10, 20, and 40 mg/day, respectively; p < 0.001). Further treatment with the dose of lovastatin at 40 mg/day (from 24 to 48 weeks) reduced LDL-cholesterol by 25% compared to placebo (p < 0.001).

In a study with pravastatin, the assessed primary efficacy outcome was the IMT, showing a significant difference between pravastatin versus placebo (p = 0.02).¹⁸ Also, pravastatin reduced LDL-cholesterol levels (-24.1%) versus placebo (+0.3%) and p < 0.001. The authors suggest that IMT findings and efficacy of treatment with pravastatin in this study should be limited to children with FH.

The efficacy results of this study were similar to others. At the end of 48 weeks, patients treated with simvastatin showed statistically significant reductions in LDL- cholesterol levels (-41%), TC (31%), APOB (-34%), very low-density lipoprotein (VLDL) cholesterol (-21%) and triglycerides (TG) (-9%).¹¹ In the study of atorvastatin versus placebo, there was an average reduction in LDL-cholesterol (40%), TC (32%), TG (12%) and APOB (34%) in the atorvastatin group compared to the placebo group (p <0.001). The increase

Original Article

								Mean difference			
Study	Total	sta Mean	tins SD	Total	piae Mean	CEDO SD			MD	95%-CI	W(random)
doce stating = high											
Avis 2010. Rosuvastatin 20 mg	44	183.00	36.00	15	293.00	18 28	-		-110.00	[_124 10: _95 90]	4.6%
Avis 2010, Rosuvastatin 10 mg	44	195.00	44 00	15	293.00	18.28	-		-98.00	[-113 96: -82 04]	4.5%
Random effects model	88	100.00	44.00	30	200.00	10.20	-		-104.61	[-116.31: -92.91]	9.1%
Heterogeneity: I-squared = 18%, tau-squared = 13, p = 0.2693										[01170
doos statina = intermediate											
uose_stattins – interineulate Broomelkeme 2015. Diteventetin 4 ma	24	200 70	41.60	07	200.00	E0 70			100.20	[107 00; 70 50]	2 59/
McCrindle 2003, Atomastatin 10 mg, 20 mg	140	10/ 00	3 10	47	202.30	9 90			- 100.20	[-127.30, -72.30]	5.3%
do longh 2002, Simulastatin 40 mg	140	10/ 00	40.09	60	293.20	56 74			-99.20	[-101.79, -30.01]	J.Z /0 1 1%
Avis 2010 Decuvertatin 40 mg	100	207.00	49.90	16	201.13	17 //			-86.00	[-100.40, -70.04]	4.4%
de Jonah 2002 Simuastatin 20 ma	106	100 50	18.62	60	255.00	57 10			-80.26	[_96.61; _63.91]	4.0%
Weaman 2004, Dravastatin 20 ma_40 ma	100	246.00	43.00	108	306.00	39.00			-60.00	[_71 00: _49 00]	4.8%
Stein 1999 Lovatatin 40 mg	63	251 22	6.06	59	308 70	7 07			-57.48	[_59.82: _55.14]	5.2%
Clauss 2005 Lovatatin 40 mg	35	223.60	46 10	19	277 70	46 10	_		-54.10	[_79.85; _28.35]	3.7%
Van der Graaf 2008 Simvastatin 40 mg/Ezetimibe 10 mg	126	167.02	3 75	120	200.20	3 79			-33.18	[-34 12: -32 24]	5.2%
Van der Graaf 2008, Simvastatin 10 mg-20 mg-40 mg/Ezetimibe 10 mg	126	179.84	3.67	120	210 15	3 76			-30.31	[-31 24: -29 38]	5.2%
Random effects model	874		0.01	654	210.10	0.10		↓ ■	-67.60	[-81.67: -53.53]	46.1%
Heterogeneity: I-squared = 99.7%, tau-squared = 463.6, p < 0.0001	••••								0.100	[0.101, 00.00]	
dees statise = law											
Cose_statuis - iow Property and 2015 Ditayortatin 2 mg	26	22/1 60	43.60	27	308.00	58 70			_84.30	[_112 07: _56 53]	3.5%
de Jonah 2002 Simvestatin 10 ma	106	206.00	43.00	60	285.62	56.60		i l	-04.50	[-112.07, -50.55]	1.5%
Stein 1999 Lovestatin 20 mg	63	200.00	6.06	60	203.02	7 07	-		-19.02	[-66.05: -61.30]	4.3%
Broomekamp 2015 Ditavastatin 1 mg	26	2/6 00	35.60	27	308.00	58 70	_		-62.00	[-88 03: -36 87]	3.6%
Kninscher 1996 Pravastatin 20 mg	18	239.08	7 68	6	294 69	5 70			-02.50	[-61 39: -49 83]	5.0%
Rodenburg 2006 Pravastatin 40 mg	90	246.80	62 10	88	300.40	56.00		昌	-53.60	[-70.96; -36.24]	4.4%
Knipscheer 1996. Pravastatin 10 mg	17	243.34	8.41	6	294.69	5.70			-51.35	[-57.41: -45.29]	5.1%
Knipscheer 1996. Pravastatin 5 mg	18	243.57	8.33	6	294.69	5.70			-51.12	[-57.09; -45.15]	5.1%
Stein 1999. Lovastatin 10 mg	63	276.66	6.06	61	318.15	7.07			-41.49	[-43.81; -39.17]	5.2%
Clauss 2005, Lovastatin 20 mg	35	237.60	54.60	19	275.80	53.70			-38.20	[-68.37; -8.03]	3.3%
Random effects model	462			369				·•	-56.96	[-65.85; -48.07]	44.8%
Heterogeneity: I-squared = 95.4%, tau-squared = 153.3, p < 0.0001											
Random effects model	1424			1053				•	-66.41	[-75.52; -57.30]	100%
Heterogeneity: I-squared = 99.4%, tau-squared = 417, p < 0.0001											
							100				
							-100	-50 0 50	100		

Figure 2 – Forest plots showing the effect of statin therapy (high, intermediate and low dose) on total cholesterol (TC) levels.

		sta	tins		pla	cebo		Mean difference			
Study	Total	Mean	SD	Total	Mean	SD			MD	95%-CI	W(random)
doso stating = high											
Avia 2010. Decuvertatin 20 mg	44	117.00	33.00	15	227.00	16 59			110.00	[122 86: 07 14]	4 7%
Avis 2010, Rosuvastatin 20 mg	44	128.00	40.00	15	227.00	16.50			00_00	[-113.40: _84.51]	4.6%
Pandom effects model	88	120.00	40.00	30	221.00	10.50			-105.00	[-115.49, -04.31] [_115.76, _04.30]	9.0%
Heterogeneity: I-squared = 19 2% tau-squared = 11 62 n = 0 2659	00			50			· ·		-105.05	[-113.70, -34.30]	3.370
neterogenety. Poquarea 10.2%, au oquarea 11.02, p 0.2000											
dose_statins = intermediate											
McCrindle 2003, Atorvastatin 10 mg-20 mg	140	131.09	2.71	47	228.93	8.12	+		-97.84	[-100.20; -95.48]	5.1%
Braamskamp 2015, Pitavastatin 4 mg	24	144.40	40.90	27	239.20	61.10	_ <u>_</u>		-94.80	[-123.06; -66.54]	3.6%
de Jongh 2002, Simvastatin 40 mg	106	125.77	48.44	69	214.85	54.51	- 		-89.08	[-104.91; -73.25]	4.5%
Avis 2010, Rosuvastatin 5 mg	42	143.00	31.00	16	227.00	15.83	- H		-84.00	[-96.17; -71.83]	4.8%
de Jongh 2002, Simvastatin 20 mg	106	133.33	46.89	69	215.91	55.69	-		-82.58	[-98.47; -66.69]	4.5%
Stein 1999, Lovatatin 40 mg	63	183.23	6.12	59	242.50	7.14	_	+	-59.27	[-61.64; -56.90]	5.1%
Clauss 2005, Lovatatin 40 mg	35	155.50	47.20	19	206.30	44.80	-		-50.80	[-76.30; -25.30]	3.8%
Van der Graaf 2008, Simvastatin 40 mg/Ezetimibe 10 mg	126	103.47	3.65	120	134.60	3.69		+	-31.13	[-32.05; -30.21]	5.1%
Van der Graaf 2008, Simvastatin 10 mg-20 mg-40 mg/Ezetimibe 10 mg	126	114.10	3.50	120	144.08	3.59		+	-29.98	[-30.87; -29.09]	5.1%
Random effects model	768			546			-		-67.85	[-83.36; -52.35]	41.6%
Heterogeneity: I-squared = 99.8%, tau-squared = 510.8, p < 0.0001											
dose_statins = low											
Braamskamp 2015, Pitavastatin 2 mg	26	158.80	38.60	27	239.20	61.10		-	-82.40	[–109.81; –54.99]	3.6%
de Jongh 2002, Simvastatin 10 mg	106	140.07	46.14	69	208.47	54.36	-	-	-68.40	[-83.95; -52.85]	4.5%
Knipscheer 1996, Pravastatin 20 mg	18	173.85	20.88	6	239.57	4.40		-	-65.72	[-75.99; -52.45]	4.9%
Stein 1999, Lovastatin 20 mg	63	190.76	6.06	60	255.00	7.14		+	-64.24	[-66.59; -61.89]	5.1%
Braamskamp 2015, Pitavastatin 1 mg	26	176.30	34.50	27	239.20	61.10		-	-62.90	[-89.49; -36.31]	3.7%
Knipscheer 1996, Pravastatin 10 mg	17	179.75	29.39	6	239.57	4.16	-	+	-59.82	[-74.18; -45.46]	4.6%
Knipscheer 1996, Pravastatin 5 mg	18	183.89	25.13	6	239.57	4.40			-55.68	[-67.81; -43.55]	4.8%
Rodenburg 2006, Pravastatin 40 mg	90	180.90	59.70	88	238.50	56.20	-		-55.60	[-72.63; -38.57]	4.4%
Wiegman 2004, Pravastatin 20 mg-40 mg	106	182.00	40.00	108	237.00	36.00			-55.00	[-65.20; -44.80]	4.9%
Stein 1999, Lovastatin 10 mg	63	208.33	6.12	61	252.00	7.07		+	-43.67	[-46.00; -41.34]	5.1%
Clauss 2005, Lovastatin 20 mg	35	168.50	53.30	19	209.00	55.50	-		-40.50	[-71.07; -9.93]	3.4%
Random effects model	568			477				•	-58.97	[-58.97; -50.11]	49.0%
Heterogeneity: I-squared = 93.8%, tau-squared = 163.3, p < 0.0001											
Bandam offerte medel	4404			4050					67.64	. 70 74	400.007
Random enects model Heterogeneity envered = 00.5% top envered = 476.6 m < 0.0004	1424			1053					-07.04	[-/0./4; -0/.35]	100.0%
neterogeneity: i-squareo = 99.5%, tau-squareo = 476.6, β < 0.0001							_				
							100	50 0 50 10	0		
							-100	-30 0 30 10	0		

Figure 3 – Forest plots showing the effect of statin therapy (high, intermediate and low dose) on low-density lipoprotein (LDL) cholesterol levels.

in HDL-cholesterol levels (2.8%) was also statistically significant.¹⁶ In the study comparing rosuvastatin versus placebo, changes in LDL-cholesterol, TC, and APOB levels were statistically significant compared to placebo for all three doses (5 mg, 10 mg, 20 mg) (p < 0.001).¹⁹

Most of the studies included in this meta-analysis focused on the effect of statins on LDL. As seen in these results in children with FH, statins are effective in lowering LDL-cholesterol and TC levels. The effectiveness of reducing the LDL-cholesterol and TC levels with statin treatment is consistent in all RCTs analyzed. The effects of statins on other levels of lipids, such as HDL-cholesterol and TG are not so consistent; that is why the results are not extrapolated to the entire pediatric population. Patients without FH must focus on changes in lifestyle first, before relying on a drug to improve their cholesterol levels.

The included studies had essential elements that determine the quality of studies, which are important for the generation of evidence. Conducting a randomized controlled trial in the pediatric population is not as common as in adults. However, there is a lack of a recognized methodology to assess the quality of pediatric studies. That is the reason why we used the clinical testing format, as used in the adult population.

The adverse event profile of a pharmacological agent is a particular concern in pediatric population. Thus, in general, data suggest that the risk of adverse events in children treated with statins are similar to those observed in adults treated with statin, at least in the short term. Studies evaluated the effect of statin therapy on clinical outcomes, hormonal status, biochemical measures of growth, nutrition and liver or kidney toxicity. For most of these parameters, there was no statistically significant difference between treatment and placebo groups. There were no reports of serious adverse events. Hepatic transaminase elevation and Creatine-phosphokinase, which are of particular concern in adults, did not differ in the studied groups.

Current guidelines for FH indicate pharmacological treatment in affected subjects between 8 to 10 years and in younger children only with extreme elevation of LDL-cholesterol and associated risk factors, having risk for premature CAD.³⁰⁻³³ Statins can be considered as first line treatment in children with HeFH and having an increase of LDL, after changes in diet and lifestyle. Response to treatment with statins should be assessed in 1 to 3 months after the start of therapy and periodically thereafter according to guidelines.34 Children treated with statins should also be frequently monitored for adverse events (for example, hepatic transaminases, creatine kinase, liver enzymes) and statins are contraindicated during pregnancy.³⁴ There is also a need for further studies to evaluate the safety of these pediatric patients throughout their lives. The results for the growth and sexual development should be considered in children under 10 years of age. Future studies should seek to include pediatric patients with secondary forms of dyslipidemia and start examining the combination of therapy in children.

However, we found some limitations in these studies. One of them is the duration of statin therapy in the included studies, which ranged from 8 to 104 weeks, whereas in the clinical practice, patients with FH are subjected to continue with statin treatment for the rest of their lives, once the therapy was initiated.³⁵ Another limitation of these studies is the conduction only in children with FH and children with secondary dyslipidemia were not included.³⁵ They also do not include information on the use of high doses of statins, such as those used in adults. Besides, the long-term efficacy data also are not available and remain unknown.

Braamskamp et al.³⁶ published the first study evaluating hormonal concentrations of FH subjects before and 10 years after the start of treatment with statins, compared with their unaffected siblings, which minimizes genetic and environmental variation between groups. Their results demonstrated that the hormone concentrations in patients with FH are among the reference range compared to their unaffected siblings.

Conclusion

Based on the evidence available in this meta-analysis, statins significantly reduced LDL-cholesterol in children with HeFH. However, there is no data regarding long-term outcomes of both effectiveness and safety.

Author contributions

Conception and design of the research: Radaelli G, Pellanda LC; Acquisition of data: Radaelli G, Sausen G; Analysis and interpretation of the data: Radaelli G, Cesa CC, Pellanda LC; Statistical analysis: Radaelli G, Cesa CC; Writing of the manuscript: Radaelli G, Sausen G, Cesa CC, Santos FS; Critical revision of the manuscript for intellectual content: Portal VL, Neyeloff JL, Pellanda LC.

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Sources of Funding

There were no external funding sources for this study.

Study Association

This article is part of the thesis of Doctoral submitted by Graciane Radaelli, from Programa de Pós Graduação -Fundação Universitária de Cardiologia (IC-FUC).

Ethics approval and consent to participate

This article does not contain any studies with human participants or animals performed by any of the authors.

References

- Bouhairie, VE, Goldberg A C. Familial hypercholesterolemia. Cardiol Clin. 2015;33(2):169-79.
- Knipscheer HC, Boelen CC, Kastelein JJ, van Diemen DE, Groenemeiyer BE, van den Ende A, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res. 1996;39(5):867-71.
- Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-37.
- Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168(1):1-14.
- Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OJ, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340(8828):1111-5.
- Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.
- Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: knowledge base, limitations, and futue directions. Pediatrics 2007;119(2):370-80.
- Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128:S213-56.
- 9. Federal Drug Authority. 2016 [access Feb. 2016]. Available from: http:// www.fda.gov
- O'Gorman CS, O'Neill M, Conwell L. Considering statins for cholesterolreduction inchildren if lifest yle and diet changes do not improve their health: a review of the risks and benefits. Vasc Health Risk Manag. 2010;7:1-14.
- Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics. 2005;116(3):682-8.
- de Jongh S, Ose L, Szamosi T, Gagné C, Lambert M, Scott R, et al. Efficacy, safety and tolerability of simvastatin in children with familial hypercholesterolaemia: Rationale, design and baseline characteristics. Clin Drug Invest. 2002;22(8):533-40.
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336-41.
- Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol. 2002;31(1):150-3.
- 15. Verzani, John. Getting Started with RStudio. California: O'Reilly Media; 2011.
- Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ. 2003;327(7414):557-60.
- McCrindle BW, Ose L, Marias DA. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;143(1):74-80.
- den Ende A, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hy-percholesterolemia. Pediatr Res. 1996;39(5):867-71.
- Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292(3):331-7.
- Rodenburg J, Vissers MN, Wiegman A, Miller ER, Ridker PM, Witztum JL, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol. 2006;47(9):1803-10.

- Avis HJ, Hutten BA, Gagné C, Langslet G, McCrindle BW, Wiegman A, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010;55(11):1121-6.
- Stein EA1, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, Jacobson MS, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999;281(2):137-44.
- van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagné C, Shi G, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008;52(17):1421-9.
- Braamskamp MJ, Stefanutti C, Langslet G, Drogari E, Wiegman A, Hounslow N, et al. "Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk." J Pediatr. 2015;167(2):338-43.
- Koeijvoets KC, Rodenburg J, Hutten BA, Wiegman A, Kastelein JJ, Sijbrands EJ. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation. 2005;112(20):3168-73.
- 26. Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de Groot E, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007;116(6):664-8.
- Ryu SK, Hutten BA, Vissers MN, Wiegman A, Kastelein JJ, Tsimikas S. Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Clin Lipidol 2011;5(1):50-6.
- Braamskamp MJ, Tsimikas S, Wiegman A, Kastelein JJ, Hutten BA. Statin therapy and secretory phospholipase A(2) in children with heterozygous familial hypercholesterolemia. Atherosclerosis 2013;229(2):404-7.
- Lambert M, Lupien PJ, Gagné C, Lévy E, Blaichman S, Langlois S, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Pediatrics. 1996;97(5):619-28.
- Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Bmj. 2003;326(7404):1423.
- Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. J Clin Lipidol. 2014;8(3):148-72.
- 32. Daniels SR, Gidding SS, de Ferranti SD; National Lipid Association Expert Panel on Familial Hypercholesterolemia.. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S30-7.
- Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, Tonstad S, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2010;7(7):CD006401.
- 34. Descamps OS, Tenoutasse S, Stephenne X, Gies I, Bealouye V, Lebrethon MC, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis. 2011;218(2):272-80.
- Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, et al. The Agenda for Familial Hypercholesterolemia A Scientific Statement From the American Heart Association. Circulation. 2015;132(22):2167-92.
- Braamskamp MJ, Kusters DM, Wiegman A, Avis HJ, Wijburg FA, Kastelein JJ, et al. Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood. Atherosclerosis. 2015;241(2):427-32.

Radaelli et al Statin treatment in children: meta-analysis

Original Article

Appendix I

PuBMed Search Strategy

- #1. Search (Child OR Adolescent)
- #2. Search (Hypercholesterolemia OR Statin OR Dyslipidemias OR Cholesterol OR Hydroxymethylglutaryl-CoA Reductase inhibitors)
- #3. Search (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized controlled trials[mh] OR random allocation [mh] OR double-

blind method[mh] OR single-blind method[mh] OR clinical trial[pt] OR clinical trials[mh] OR ("clinical trial"[tw]) OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND (mask*[tw] OR blind*[tw])) OR ("latin quare"[tw]) OR placebos[mh] OR placebo*[tw] OR random*[tw] OR research design[mh:noexp] OR comparative studies[mh] OR evaluation studies[mh] OR follow-up studies[mh] OR prospective studies[mh] OR crossover studies[mh] OR control* [tw] OR prospectiv*[tw] OR olunteer*[tw]) NOT (animal[mh] NOT human[mh])

#4. Search (#1 AND #2 AND #3)

Appendix II

Study Total Mean SD Total Mean SD Total Mean SD Mean Mean SD Avis 2010, Rosuvastatin 20 mg 44 183.00 36.00 15 293.00 18.28 - - -110.00 [-124.10, -95.00] Mix Braamskamp 2015, Pitavastatin 10 mg-20 mg 44 195.00 41.00 31.00 72 308.90 58.70 -											
Study Total Mean SD Total Mean SD Total Mean SD MD 95%-C1 WI Avis 2010, Rosuvastain 20 mg 44 183.00 36.00 15 293.00 18.28			sta	tins		plac	cebo	Mean difference			
Avis 2010, Rosuvastatin 20 mg 44 183.00 36.00 15 293.00 18.28 -110.00 [-124.10; -95.90] Braamskamp 2015, Pitavastatin 4 mg 24 208.70 41.60 27 308.90 58.70 -10.020 [-127.90, -72.50] McCindle 2003, Alorvastatin 10 mg-20 mg 140 194.00 43.00 76 293.00 18.28 -10.020 [-11.396, -82.04] de Jongh 2002, Sinvastatin 40 mg 106 194.09 49.98 69 281.15 56.74 -4 -87.06 [-10.348, -70.64] Avis 2010, Rosuvastatin 20 mg 106 194.09 49.98 69 281.15 56.74 -4 -87.06 [-10.348, -70.64] Avis 2010, Rosuvastatin 20 mg 106 199.50 48.62 69 279.76 57.10 -6 -66.05, -61.391 -90.26 [-96.61; -63.91] de Jongh 2002, Sinvastatin 10 mg 106 206.00 37.58 6.06 60 27.308.90 8.70 -7 -79.62 [-96.65; -61.39] Braamskamp 2015, Pitavastatin 10 mg 106 246.00 35.60 27 308.90 8.70 -6<	Study	Total	Mean	SD	Total	Mean	SD		MD	95%-CI	W(rando
Braanskamp 2015, Pitavastatin 4 mg 24 208.70 14.60 27 30.890 58.70 -100.20 [-127.90, -725.00] McCrindle 2003, Aloxavastatin 10 mg-20 mg 140 194.00 3.10 47 293.20 8.89 -99.20 [-101.79, -26.61] McCrindle 2003, Aloxavastatin 10 mg 44 195.00 44.00 15 293.00 15.74 -87.06 [-103.48, -70.64] Avis 2010, Rosuvastatin 5 mg 44 207.00 37.00 16 293.00 17.44 -86.00 [-100.08, -71.92] Braamskamp 2015, Pitavastatin 2 mg 26 224.60 43.60 27 30.89 58.70 -84.20 -80.26 [-96.61; -65.391] de Jongh 2002, Sinvastatin 10 mg 106 199.50 48.62 69 275.76 57.10 -79.62 [-96.61; -63.91] Braamskamp 2015, Pitavastatin 10 mg 106 206.00 35.60 27 30.890 58.70 -62.90 [-88.93, -36.87] Shin 1999, Lowastatin 20 mg 106 246.00 35.60 27 30.890 58.70 -62.90 [-88.93, -36.87] Shin 1999, Lowastatin 10 mg <td>Avis 2010, Rosuvastatin 20 mg</td> <td>44</td> <td>183.00</td> <td>36.00</td> <td>15</td> <td>293.00</td> <td>18.28</td> <td>₽ ! </td> <td>-110.00</td> <td>[-124.10; -95.90]</td> <td>4.</td>	Avis 2010, Rosuvastatin 20 mg	44	183.00	36.00	15	293.00	18.28	₽ !	-110.00	[-124.10; -95.90]	4.
McCrindle 2003, Alorvastatin 10 mg 140 194.00 3.10 47 293.20 8.89 -99.20 [-101.79, -96.61] Avis 2010, Rosuvastatin 10 mg 44 195.00 44.00 15 293.00 16.28 -97.06 [-113.96, -82.04] Avis 2010, Rosuvastatin 40 mg 106 194.09 49.98 69 281.15 56.74 -97.06 [-113.36, -70.64] Braamskamp 2015, Pitavastatin 2 mg 26 224.60 43.80 27 30.80 58.70 -98.20 [-410.08, -71.92] Braamskamp 2015, Pitavastatin 20 mg 106 199.50 48.62 69 279.76 57.10 -84.30 [-112.07, -56.53] Stein 1999, Lovastatin 20 mg 106 295.08 66.66 03 21.30 7.07 -83.72 [-66.05, -61.39] Braamskamp 2015, Pitavastatin 10 mg 26 246.00 43.00 108 30.00 -63.72 [-66.05, -61.39] Braamskamp 2015, Pitavastatin 20 mg 106 291.00 7.07 -62.90 [-88.93, -65.74] -62.90 [-88.93, -65.74] -62.90 [-61.38, -42.49] -61.00 [-71.00, -49.00] -62.90	Braamskamp 2015, Pitavastatin 4 mg	24	208.70	41.60	27	308.90	58.70	- B	-100.20	[-127.90; -72.50]	3.
Avis 2010, Rosuvastatin 10 mg 44 195.00 44.00 15 23.00 18.28	McCrindle 2003, Alorvastatin 10 mg-20 mg	140	194.00	3.10	47	293.20	8.89	•	-99.20	[-101.79; -96.61]	5.
e Jorgh 2002, Simvastatin 40 mg 106 194.09 49.8 69 281.15 56.74	wis 2010, Rosuvastatin 10 mg	44	195.00	44.00	15	293.00	18.28	_ ⊒ :	-98.00	[-113.96; -82.04]	4.
vis 2010, Rosuvastatin 5 mg 44 207.00 37.00 16 293.00 17.44	e Jongh 2002, Simvastatin 40 mg	106	194.09	49.98	69	281.15	56.74		-87.06	[-103.48; -70.64]	4.
raamskamp 2015, Pitavastatin 2 mg 26 224.60 33.60 27 30.80 58.70	vis 2010, Rosuvastatin 5 mg	44	207.00	37.00	16	293.00	17.44	- -	-86.00	[-100.08; -71.92]	4.
ie Jongh 2002, Simvastatin 20 mg 106 199.50 48.82 69 279.76 57.10 -00.26 96.61:-63.91] ie Jongh 2002, Simvastatin 10 mg 106 200.00 47.82 69 286.2 56.69 79.62 [-96.61:-63.91] itein 1999, Lowsstatin 20 mg 63 257.58 6.06 60 321.30 7.07 I 62.90 [-88.93], -36.87] Veigman 2004, Pitavastatin 20 mg 106 240.00 35.60 27 308.90 58.70 62.90 [-88.93], -36.87] Veigman 2004, Pitavastatin 20 mg 106 240.00 43.00 108 306.00 39.00 62.90 [-88.93], -36.87] Inipscheer 1996, Pravastatin 20 mg 106 240.00 43.00 108 30.80 -70.7 55.61 [-61.39], -49.83] Jauss 2005, Lovastatin 40 mg 35 22.60 46.10 19 277.77 46.10 54.10 [-79.85, -25.51.4] Inipscheer 1996, Pravastatin 40 mg 10 22.36 46.10 19 277.77 47.10 64.10 [-79.85, -24.51.4] Inipscheer 1996, Pravastatin 10 mg	Braamskamp 2015, Pitavastatin 2 mg	26	224.60	43.60	27	308.90	58.70		-84.30	[-112.07; -56.53]	3.
e Jongh 2002, Simvastatin 10 mg 106 206.00 47.82 69 285.62 56.69 -79.62 [-95.80; -63.44] tein 1999, Lovastatin 20 mg 63 257.58 60 60 321.30 7.07 -63.72 [-66.05; -61.39] veigman 2004, Pitavastatin 20 mg 26 246.00 35.60 277.73 60 -79.62 [-95.80; -63.44] veigman 2004, Pitavastatin 20 mg 26 246.00 35.60 27 308.90 68.70 -60.00 [-71.00; -49.00] tein 1999, Lovastatin 40 mg 63 251.22 60.6 59 308.70 7.07 -57.48 [-59.82; -55.14] Juss 2005, Lovastatin 40 mg 18 239.08 7.68 6 294.69 5.70 -55.61 [-61.39; -49.83] Juss 2005, Lovastatin 40 mg 10 277.70 61.0 -54.10 [-79.85; -28.35] -55.61 [-61.39; -49.83] Juss 2005, Lovastatin 10 mg 17 245.37 8.33 6 294.69 5.70 -51.35 [-57.41; -45.29] Inipscheer 1996, Pravastatin 10 mg 18 245.57 8.33 6 294.69 <td>e Jongh 2002, Simvastatin 20 mg</td> <td>106</td> <td>199.50</td> <td>48.62</td> <td>69</td> <td>279.76</td> <td>57.10</td> <td>-Bi</td> <td>-80.26</td> <td>[-96.61; -63.91]</td> <td>4.</td>	e Jongh 2002, Simvastatin 20 mg	106	199.50	48.62	69	279.76	57.10	- B i	-80.26	[-96.61; -63.91]	4.
tein 1999, Lovastatin 20 mg 63 257.58 6.06 60 321.30 7.07 -63.72 i=66.05; -61.39 raamskamp 2015, Pitavastatin 20 mg 26 26.00 3.00 -62.90 i=8.93; -36.87 (eigman 2004, Pitavastatin 20 mg 166 246.00 43.00 108 30.00 -62.90 i=8.93; -36.87 tein 1999, Lovastatin 40 mg 63 251.22 6.06 59 30.870 7.07 -57.48 i=59.82; -55.14 nipscheer 1996, Pravastatin 40 mg 35 223.60 46.10 19 277.70 46.10 -55.61 i=61.39; -49.83 aluass 2005, Lovastatin 40 mg 90 246.80 62.10 88 30.04 66.00 -53.60 i=7.09; -36.24 nipscheer 1996, Pravastatin 10 mg 17 243.34 8.41 6 294.69 5.70 -51.35 i=57.41; -45.29 nipscheer 1996, Pravastatin 10 mg 18 243.57 8.31 6 294.69 5.70 -51.32 i=57.41; -45.29 nipscheer 1996, Pravastatin 10 mg 13 257.66 6.06 61 18.15 7.07 -41.49	e Jongh 2002, Simvastatin 10 mg	106	206.00	47.82	69	285.62	56.69	- F	-79.62	[-95.80; -63.44]	4.
raamskamp 2015, Pitavastatin 1 ng 26 246.00 35.00 27 308.90 58.7062.90 [-68.93; -36.87] //eigman 2004, Pitavastatin 20 ng-40 ng 200 [-71.00; -49.00] inipscheer 1996, Pravastatin 20 ng 18 239.08 7.68 62 294.69 5.70 - 57.48 [-59.82; -55.14] nipscheer 1996, Pravastatin 40 ng 35 223.60 46.10 19 277.70 46.1057.48 [-59.82; -55.14] nipscheer 1996, Pravastatin 40 ng 02 446.80 62.10 88 300.40 65.0053.60 [-71.00; -49.03] inipscheer 1996, Pravastatin 10 ng 17 243.34 8.41 62 294.69 5.70 - 57.81 [-61.33; -49.83] inipscheer 1996, Pravastatin 10 ng 17 243.34 8.41 62 294.69 5.70 - 57.81 [-57.41; -45.29] inipscheer 1996, Pravastatin 10 ng 18 243.57 8.33 62 294.69 5.70 [-57.41] - 51.32 [-57.41; -45.29] inipscheer 1996, Pravastatin 10 ng 18 243.57 8.33 62 294.69 5.70 [-57.41] - 51.32 [-57.41; -45.29] inipscheer 1996, Pravastatin 10 ng 18 243.57 8.33 62 294.69 5.70 [-57.41] - 51.32 [-57.41; -45.29] inipscheer 1996, Pravastatin 10 ng 13 276.66 6.06 6.10 18 18 5.70 [-41.49 [-43.81; -39.17] Iauss 2005, Lovastatin 40 mg 23 276.60 5.70 [-57.41] - 43.81; -39.17] Iauss 2005, Lovastatin 10 ng 20 ng–40 ng/Ezetimibe 10 ng 12 6 167.02 3.75 120 20.20 3.79 [-33.18 [-34.12; -32.24] an der Graff 2008, Sinvastatin 10 ng -20 ng–40 ng/Ezetimibe 10 ng 12 6 179.84 3.77 120 210.15 3.76 [-37.40] [-33.18 [-34.12; -32.24] and der Graff 2008, Sinvastatin 10 ng -20 ng–40 ng/Ezetimibe 10 ng 12 6 179.84 3.77 120 210.15 3.76 [-37.40] [-30.31 [-31.24; -32.8]]	tein 1999, Lovastatin 20 mg	63	257.58	6.06	60	321.30	7.07	+	-63.72	[-66.05; -61.39]	5.
feigman 2004, Pitavastatin 20 mg-40 mg 106 246.00 43.00 108 306.00 39.00 -60.00 [-71.00; -49.00] -57.48 [-59.82; -55.14] pipscheer 1996, Pravastatin 20 mg 18 239.08 7.68 6 59.46 57.0 -57.48 [-59.82; -55.14] -55.61 [-61.39; -49.83] pipscheer 1996, Pravastatin 40 mg 35 23.60 46.10 19 277.70 46.10 -54.10 [-79.85; -28.35] -65.61 [-61.39; -49.83] pipscheer 1996, Pravastatin 40 mg 90 246.80 62.10 88 30.040 66.00 -57.8 [-57.41; -45.29] -53.60 [-70.96; -35.64] [-73.85; -28.35] [-57.41; -45.29] -51.35 [-57.41; -45.29] -51.35 [-57.41; -45.29] -51.35 [-57.41; -45.29] -51.35 [-57.41; -45.29] -51.35 [-57.41; -45.29] -51.12 [-57.43; -43.15] -51.12 [-57.41; -45.29] -51.12 [-57.41; -45.29] -51.12 [-57.41; -45.29] -51.25 [-57.41; -45.29] -51.35 [-68.37; -83.43] -51.25 [-57.41; -45.29] -51.25 [-57.41; -45.29] -51.25 [-57.41; -45.29] -51.35 <td< td=""><td>raamskamp 2015, Pitavastatin 1 mg</td><td>26</td><td>246.00</td><td>35.60</td><td>27</td><td>308.90</td><td>58.70</td><td><u> </u></td><td>-62.90</td><td>[-88.93; -36.87]</td><td>3.</td></td<>	raamskamp 2015, Pitavastatin 1 mg	26	246.00	35.60	27	308.90	58.70	<u> </u>	-62.90	[-88.93; -36.87]	3.
ein 1999, Lovastatin 40 mg 63 251.22 6.06 59 308.70 7.07 -57.48 -59.82; -55.14 inpscheer 1996, Pravastatin 70 mg 18 239.08 7.68 6 294.69 5.70 -57.48 -59.82; -55.14 uses 2005, Lovastatin 40 mg 35 223.60 46.10 197.70 -57.46 -57.48 -59.82; -55.14 odenburg 2006, Pravastatin 40 mg 30 246.80 62.10 88 300.40 56.00 -53.60 -57.41 -59.82; -55.14 inpscheer 1996, Pravastatin 10 mg 17 243.34 84.1 6 294.69 5.70 -51.35 -57.41; -45.29 inipscheer 1996, Pravastatin 10 mg 18 243.57 8.33 6 294.69 5.70 -51.35 -57.41; -45.29 inipscheer 1996, Pravastatin 10 mg 18 243.57 8.33 6 294.69 5.70 -41.49 -43.81; -39.171 lauss 2005, Lovastatin 20 mg 35 237.60 54.60 19 275.80 53.70 -38.20 -68.37; -80.33 an der Graff 2008, Simvastatin 10 mg 126 167.02 3.75	leigman 2004, Pitavastatin 20 mg-40 mg	106	246.00	43.00	108	306.00	39.00		-60.00	[-71.00; -49.00]	4.
nipscheer 1996, Pravastatin 40 mg dorbhurg 2006, Pravastatin 40 mg 35 223.60 46.10 19 277.70 46.10	tein 1999, Lovastatin 40 mg	63	251.22	6.06	59	308.70	7.07	+	-57.48	[-59.82; -55.14]	5.
Jauss 2005, Lovastatin 40 mg 35 223.60 46.10 19 277.70 46.10	nipscheer 1996, Pravastatin 20 mg	18	239.08	7.68	6	294.69	5.70	I	-55.61	[-61.39; -49.83]	5.
odenburg 2006, Pravastatin 40 mg 90 246.80 62.10 88 300.40 56.00 -53.60 [-70.96; -36.24] nipscheer 1996, Pravastatin 10 mg 17 243.34 8.41 6 294.69 5.70 -51.35 [-57.41; +45.29] nipscheer 1996, Pravastatin 10 mg 18 245.76 8.33 6 294.69 5.70 -51.25 [-57.41; +45.29] tein 1999, Lovastatin 10 mg 63 276.66 6.06 61 318.15 7.07 -41.49 [-43.81; -39.17] lauss 2005, Lovastatin 20 mg 35 237.60 54.00 19 275.80 53.70 -38.20 [-68.37; -8.03] an der Graff 2008, Simvastatin 40 mg/Ezetimibe 10 mg 12 167.02 3.75 120 202.02 3.79 -33.18 [-31.24; -29.38] an der Graff 2008, Simvastatin 10 mg-20 mg-40 mg/Ezetimibe 10 mg 12 179.84 3.67 120 210.15 3.76 -30.31 [-31.24; -29.38]	lauss 2005, Lovastatin 40 mg	35	223.60	46.10	19	277.70	46.10		-54.10	[-79.85; -28.35]	3.
nipscheer 1996, Pravastatin 10 mg 17 243.34 84.1 6 294.69 5.70 Image: Constraint of the state of the st	odenburg 2006, Pravastatin 40 mg	90	246.80	62.10	88	300.40	56.00		-53.60	[-70.96; -36.24]	4.
nipscheer 1996, Pravastatin 5 mg 18 243.57 8.33 6 294.69 5.70 Image: Constraint of the second sec	nipscheer 1996, Pravastatin 10 mg	17	243.34	8.41	6	294.69	5.70	+	-51.35	[-57.41; -45.29]	5.
tein 1999, Lovastatin 10 mg 63 276.66 6.06 61 318.15 7.07 Image: Constant 10 mg -41.49 [-43.81; -39.17] lauss 2005, Lovastatin 20 mg 35 237.60 54.60 19 275.80 53.70 Image: Constant 10 mg -38.20 [-68.37; -8.03] an der Graff 2008, Simvastatin 40 mg/Ezetimibe 10 mg 126 167.02 3.75 120 200.20 3.79 Image: Constant 10 mg -33.18 [-34.12; -32.24] an der Graff 2008, Simvastatin 10 mg-20 mg-40 mg/Ezetimibe 10 mg 126 179.84 3.67 120 210.15 3.76 Image: Constant 10 mg -30.31 [-31.24; -29.38]	nipscheer 1996, Pravastatin 5 mg	18	243.57	8.33	6	294.69	5.70	: ••	-51.12	[-57.09; -45.15]	5.
lauss 2005, Lovastatin 20 mg 35 237.60 54.60 19 275.80 53.70	tein 1999, Lovastatin 10 mg	63	276.66	6.06	61	318.15	7.07		-41.49	[-43.81; -39.17]	5.
an der Graff 2008, Simvastatin 40 mg/Ezetimibe 10 mg 126 167.02 3.75 120 200.20 3.79 an der Graff 2008, Simvastatin 10 mg–20 mg–40 mg/Ezetimibe 10 mg 126 179.84 3.67 120 210.15 3.76 3.76 -30.31 [-31.24; -29.38]	lauss 2005, Lovastatin 20 mg	35	237.60	54.60	19	275.80	53.70		-38.20	[-68.37; -8.03]	3.
an der Graff 2008, Simvastatin 10 mg-20 mg-40 mg/Ezetimibe 10 mg 126 179.84 3.67 120 210.15 3.76 -30.31 [-31.24; -29.38]	an der Graff 2008, Simvastatin 40 mg/Ezetimibe 10 mg	126	167.02	3.75	120	200.20	3.79	•	-33.18	[-34.12; -32.24]	5.
	an der Graff 2008, Simvastatin 10 mg–20 mg–40 mg/Ezetimibe 10 mg	126	179.84	3.67	120	210.15	3.76		-30.31	[-31.24; -29.38]	5.
andom effects model 1424 1053 \blacklozenge -66.41 [-75.52; -57.30]	andom effects model	1424			1053			•	-66.41	[-75.52; -57.30]	10

Appendix 2 – Forest plots showing the effect of statin therapy on total cholesterol (TC) levels.

Appendix III

			statins		pla	cebo	Mean difference			
Study	Total	Mean	SD	Total	Mean	SD		MD	95%-CI	W(random)
Avis 2010 Rosuvastatin 20 mg	44	117 00	33.00	15	227 00	16 58		_110.00	[_122 86: _97 14]	4 7%
Avis 2010 Rosuvastatin 10 mg	44	128.00	40.00	15	227.00	16.58		-99.00	[-113.49: -84.51]	4.6%
McCrindle 2003 Atorvastatin 10 mg-20 mg	140	131.09	2 71	47	228.93	8 12		-97.84	[-100.20; -95.48]	5.1%
Braamskamp 2015. Pitavastatin 4 mg	24	144 40	40.90	27	239.20	61 10		-94.80	[-123.06; -66.54]	3.6%
de Jonah 2002 Simvastatin 40 ma	106	125 77	48 44	69	214.85	54 51		-89.08	[-104 91: -73 25]	4.5%
Avis 2010 Resuvestatio 5 mg	42	143.00	31.00	16	227 00	15.83		_84.00	[_96 17: _71 83]	4.8%
de Jongh 2002 Simvastatin 20 mg	106	133.33	46.89	69	215.91	55.69		-82.58	[-98.47: -66.69]	4.5%
Braamskamp 2015. Pitavastatin 2 mg	26	156.80	38.60	27	239.20	61 10		-82.40	[-109.81: -54.99]	3.6%
de Jonah 2002 Simvestetin 10 ma	106	140.07	46 14	69	203.20	54.36		_68.40	[_83.95; _52.85]	4 5%
Kninscheer 1996 Pravastatin 20 mg	18	173.85	20.88	6	239.57	4.40	出	_65.72	[-75.99: -55.45]	4.0%
Stein 1999 Lovastatin 20 mg	63	190.76	6.06	60	255.00	7 14		_64.24	[-66.59; -61.89]	5.1%
Braamskamp 2015. Pitavastatin 1 mg	26	176 30	34.50	27	239.20	61 10		_62.90	[_89.49; _36.31]	3.7%
Kninscheer 1996 Pravastatin 10 mg	17	179.75	20 30	6	239.57	4 16	「「「」」	_59.82	[-74 18: _45 46]	4.6%
Stein 1999 Lovastatin 40 mg	63	183 23	6.12	59	242 50	7 14		_59.27	[-61 64: -56 90]	5.1%
Kninscheer 1996 Pravastatin 5 mg	18	183.89	25.13	6	239.57	4.40	二 二 二 二 二 二 二 二 二 二 二 二 二 二 二 二 二 二 二	-55.68	[-67.81; -43.55]	4.8%
Rodenburg 2006. Pravastatin 40 mg	90	180.90	59 70	88	236.50	56.20		-55.60	[-72 63; -38 57]	4.0%
Weigman 2004 Pravastatin 20 mg-40 mg	106	182.00	40.00	108	237.00	36.00		-55.00	[-65 20; -44 80]	4.4%
Clause 2005 Lovastatin 40 mg	35	155.50	47.20	100	206.30	44.80		-50.80	[-76 30; -25 30]	3.8%
Stein 1999 Lovastatin 10 mg	63	208 33	6.12	61	252.00	7.07		_43.67	[_46 00; _41 34]	5.1%
Clause 2005 Lovastatin 20 mg	35	168 50	53 30	10	202.00	55.50		40.50	[71 07: 0.03]	3.4%
Van der Graaf 2008, Simvastatin 40 mg/Ezetimihe 10 mg	126	103.00	3.65	120	134.60	3 60		-40.00	[32.05 30.21]	5.1%
Van der Graaf 2000, Simvastatin 40 mg/Ezeimibe 10 mg	120	11/ 10	3.00	120	144.00	3.50		20.08	[-32.03, -30.21]	5.1%
van der Graar 2000, Omraataan 10 mg-20 mg-40 mgrezeanlibe 10 mg	120	114.10	0.00	120	144.00	0.00	•	-23.30	[-50.07, -25.09]	J.176
Random effects model	1424			1053			↓	-67.04	[-76.74; -57.35]	100%
Heterogeneity: I-squared = 99.5%, tau-squared = 416.6, p < 0.0001										
							100 50 0 50	100		
							-100 -50 0 50	100		

Appendix 3 – Forest plots showing the effect of statin therapy on low-density lipoprotein (LDL) cholesterol levels

Appendix IV

Study Image: Study											
Study Total Mean SD Total Mean SD Total Mean SD Total Mean SD Mol 95%-Cl W(random) Braamskamp 2015, Pitavastalin 2 mg 26 49.80 9.80 27 52.90 10.90 -3.10 [-8.68; 2.48] 1.6% Braamskamp 2015, Pitavastalin 2 mg 27 50.20 10.60 27 52.90 10.90 -2.70 [-8.43; 3.03] 1.6% Weigman 2004, Pitavastalin 2 mg 106 44.41 10.00 108 48.48 9.00 -2.70 [-8.43; 3.03] 1.6% Van der Graff 2008, Sinwastalin 40 mg/Ezetimibe 10 mg 126 47.66 0.66 120 47.47 0.87 0.19 -2.398; 3.89 2.8% Van der Graff 2008, Sinwastalin 10 mg-20 mg-40 mg/Ezetimibe 10 mg 126 47.66 0.86 120 47.47 0.87 0.19 -0.01 [-2.58; 1.087] 0.5% Knipscheer 1996, Pravastalin 10 mg 126 49.00 12.10 88 49.90 10.50 0			st	atins		pla	cebo	Mean difference			
Braamskamp 2015, Pitavastalin 4 mg 26 49.80 9.80 27 52.90 10.90 -3.10 [-8.68; 2.48] 1.6% Braamskamp 2015, Pitavastalin 2 mg 27 50.20 10.60 27 52.90 10.90 -2.70 [-8.43; 3.03] 1.6% Weigman 2004, Pitavastalin 2 mg 106 48.41 10.00 108 48.48 9.00 -0.07 [-2.62; 2.48] 5.0% Avis 2010, Rosuvastatin 5 mg 42 48.00 12.00 15 48.00 3.23 -0.00 [-38; 3.98] 2.8% Van der Graff 2008, Simvastatin 10 mg 126 47.66 0.86 120 47.47 0.87 0.89 0.22 [0.00, 0.44] 10.9% Knipscheer 1996, Pravastatin 10 mg 126 49.00 0.87 12.10 88.48 9.00 -0.51 [-9.65; 10.67] 0.5% Rodenburg 2006, Pravastatin 10 mg 106 49.05 10.13 69 48.08 14.05 -0.97 [-2.87; 4.81] 3.0% Stein 1999, Lovastatin 10 mg 106 49.05 10.13 69 48.08 14.05 -0.97 [-2	Study	Total	Mean	SD	Total	Mean	SD		MD	95%-CI	W(random)
Braamskamp 2015, Pitvastalin 4 mg 26 48.0 9.80 27 52.90 10.90 3.10 [-8.68; 2.48] 1.6% Braamskamp 2015, Pitvastalin 2 ng 27 50.20 10.60 27 52.90 10.90											
Braamskamp 2015, Pitavastatin 2 mg 27 50.20 10.60 27 52.90 10.90	Braamskamp 2015, Pitavastatin 4 mg	26	49.80	9.80	27	52.90	10.90		-3.10	[-8.68; 2.48]	1.6%
Weigman 2004, Plavastatin 20 mg-40 mg 106 48.4 10.00 108 48.48 9.00	Braamskamp 2015, Pitavastatin 2 mg	27	50.20	10.60	27	52.90	10.90	0 ;	-2.70	[-8.43; 3.03]	1.6%
Avis 2010, Rosuvastatin 5 mg 42 48.00 12.00 15 48.00 32.33	Weigman 2004, Pitavastatin 20 mg-40 mg	106	48.41	10.00	108	48.48	9.00		-0.07	[-2.62; 2.48]	5.0%
Van der Graff 2008, Sinwastalin 40 mg/Ezetimibe 10 mg 126 47.66 0.86 120 47.47 0.87 0.19 [-0.03; 0.41] 10.9% Van der Graff 2008, Sinwastalin 10 mg-20 mg-40 mg/Ezetimibe 10 mg 126 49.00 0.87 120 48.78 0.89 0.22 [0.00; 0.44] 10.9% Knipscheer 1996, Pravastalin 10 mg 18 44.88 16.13 6 44.37 9.00 0.51 [-9.85; 10.87] 0.5% Rodenburg 2006, Pravastalin 40 mg 90 50.70 12.10 88 49.90 10.50 0.80 [-2.53; 4.13] 3.6% de Jongh 2002, Sinwastalin 20 mg 106 40.05 10.13 69 40.80 14.05 14.48 11.21; 14.41 10.7% McCrindle 2003, Alorxastalin 10 mg-20 mg 63 46.80 1.02 60 45.24 1.55 1.55 [1.06; 2.02] 10.6% de Jongh 2002, Sinwastalin 10 mg-20 mg 106 50.20 10.01 69 48.21 13.57 1.55 [1.06; 2.02] 10.6% de Jongh 2002, Sinwastalin 10 mg 26 50.20 10.01 64 80.03 3.38	Avis 2010, Rosuvastatin 5 mg	42	48.00	12.00	15	48.00	3.23	- <u>-</u>	0.00	[-3.98; 3.98]	2.8%
Van der Graff 2008, Sinwastalin 10 mg-20 mg-40 mg/Ezetlinibe 10 mg 126 49.00 0.87 120 48.78 0.89 0.22 [0.00, 0.44] 10.9% Knipscheer 1996, Pravastalin 10 mg 18 44.88 16.13 6 44.37 9.00 0.51 [-9.85; 10.87] 0.5% Rodenburg 2006, Pravastalin 10 mg 90 50.70 12.10 88 49.90 10.50 0.80	Van der Graff 2008, Simvastatin 40 mg/Ezetimibe 10 mg	126	47.66	0.86	120	47.47	0.87	+	0.19	[-0.03; 0.41]	10.9%
Knipscheer 1996, Pravastatin 10 mg 18 44.88 16.13 6 44.37 9.00 - 0.51 [-9.85; 10.87] 0.5% Rodenburg 2006, Pravastatin 10 mg 90 50.70 12.10 88 49.90 10.50 - 0.80 [-2.53; 4.81] 3.0% Get Jong 2002, Simvastatin 20 mg 106 49.05 1.13 69 48.08 14.05 - 0.97 [-2.87; 4.81] 3.0% Stein 1999, Lovastatin 20 mg 63 46.80 1.02 60 45.22 1.04 1.48 [1.12; 1.84] 10.7% McCindiel 2002, Sinvastatin 10 mg-20 mg 106 50.20 10.01 69 48.21 13.57 - 1.48 [1.12; 1.84] 10.7% de Jongh 2002, Sinvastatin 10 mg 106 50.20 10.01 69 48.21 13.57 - 1.99 [-1.74; 5.72] 3.1% Avis 2010, Rosuvastatin 20 mg 44 50.00 13.00 16 48.00 3.38 - - 2.00 [-2.16; 6.18] 2.6% Braamskamp 2015, Pitavastatin 11 mg 26 55.30 13.02	Van der Graff 2008, Simvastatin 10 mg–20 mg–40 mg/Ezetimibe 10 mg	126	49.00	0.87	120	48.78	0.89	+	0.22	[0.00; 0.44]	10.9%
Rodenburg 2006, Pravastatin 40 mg 90 50.7 12.10 88 49.90 10.50 10.80 [-2.53, 4.13] 3.6% de Jongh 2002, Simvastatin 20 mg 106 49.05 10.13 69 48.08 14.05 1.48 [1.12, 18.14] 10.7% Stein 1999, Lowastatin 20 mg 63 46.80 1.02 60 45.32 1.04 1 1.48 [1.12, 18.14] 10.7% McCrindle 2003, Alovastatin 10 mg-20 mg 140 46.79 0.90 47 45.24 1.55 1.99 [-1.74, 5.72] 3.1% de Jongh 2002, Simvastatin 10 mg 106 50.00 13.00 16 48.00 3.38 1.99 [-1.74, 5.72] 3.1% Avis 2010, Rosuvastatin 20 mg 44 50.00 13.00 16 48.00 3.38 2.00 [-2.18; 6.18] 2.6% BraamsKamp 2015, Pitavastatin 1 mg 26 53.00 13.20 27 52.90 10.90 2.40 [-4.13;	Knipscheer 1996, Pravastatin 10 mg	18	44.88	16.13	6	44.37	9.00		0.51	[-9.85; 10.87]	0.5%
de Jongh 2002, Sinvastatin 20 mg 106 49.05 10.13 69 48.08 14.05 11 097 [-2.87, 4.81] 3.0% Stein 1999, Lovastatin 20 mg 63 46.80 1.02 60 45.32 1.04 1.48 [1.12; 1.84] 10.7% McCinnel 2003, Alorvastatin 10 mg-20 mg 140 46.79 0.90 47 45.24 1.55 1.55 1.55 1.08 [1.02; 1.84] 10.7% de Jongh 2002, Sinvastatin 10 mg 106 50.20 10.01 69 48.21 13.57 1.55 1.55 1.08 1.25 1.14 1.14, 57.2] 3.1% Avis 2010, Rosuvastatin 20 mg 44 50.00 13.00 16 48.00 3.38 100 1.24 1.55 1.25 2.00 [-2.18; 6.18] 2.6% BraamsKamp 2015, Pitavastatin 11 mg 26 55.30 13.02 27 52.90 10.90 1.26 2.40 [-4.13; 8.33] 1.3%	Rodenburg 2006, Pravastatin 40 mg	90	50.70	12.10	88	49.90	10.50	 0 	0.80	[-2.53; 4.13]	3.6%
Stein 1999, Lovastatin 20 mg 63 46.80 1.02 60 45.32 1.04 1.48 [1.12, 1.84] 10.7% McCinidle 2003, Alorvastatin 10 mg-20 mg 140 46.79 0.90 47 45.24 1.55 1.55 [1.08, 2.02] 10.6% de Jongh 2002, Simvastatin 10 mg-20 mg 106 50.20 10.01 69 48.21 13.57 1.59 [1.12, 1.54] 1.6% Avis 2010, Rosuvastatin 20 mg 106 50.00 13.00 16 48.00 3.38 10 - 1.6% - - - - - - - - - - - - <t< td=""><td>de Jongh 2002, Simvastatin 20 mg</td><td>106</td><td>49.05</td><td>10.13</td><td>69</td><td>48.08</td><td>14.05</td><td></td><td>0.97</td><td>[-2.87; 4.81]</td><td>3.0%</td></t<>	de Jongh 2002, Simvastatin 20 mg	106	49.05	10.13	69	48.08	14.05		0.97	[-2.87; 4.81]	3.0%
McCrindle 2003, Alovastatin 10 mg-20 mg 140 46.79 0.90 47 45.24 1.55 Image: State 1 1.55 [1.08; 2.02] 10.6% de Jongh 2002, Simwastatin 10 mg 106 50.20 10.01 69 48.21 13.57 Image: State 1 1.99 [-1.74; 5.72] 3.1% Avis 2010, Rosuvastatin 20 mg 44 50.00 13.00 16 48.00 3.38 Image: State 1 2.00 [-2.16; 6.18] 2.6% Braamskamp 2015, Pitavastatin 1 mg 26 55.30 13.20 27 52.90 10.90 Image: State 1 2.40 [-4.13; 8.33] 1.3%	Stein 1999, Lovastatin 20 mg	63	46.80	1.02	60	45.32	1.04	+	1.48	[1.12; 1.84]	10.7%
de Jongh 2002, Simwastatin 10 mg 106 50.20 10.01 69 48.21 13.57 199 [-1.74; 5.72] 3.1% Avis 2010, Rosuvastatin 20 mg 44 50.00 13.00 16 48.00 3.38 199 [-1.74; 5.72] 3.1% Braamskamp 2015, Pitavastatin 1 mg 26 55.30 13.20 27 52.90 10.90 -1413, 533] 1.3%	McCrindle 2003, Alorvastatin 10 mg–20 mg	140	46.79	0.90	47	45.24	1.55	+	1.55	[1.08; 2.02]	10.6%
Avis 2010, Rosuvastatin 20 mg 2.00 [-2.18; 6.18] 2.6% Braamskamp 2015, Pitavastatin 1 mg 2.6 55.30 13.20 27 52.90 10.90 - 100 [-4.13; 8.93] 1.3%	de Jongh 2002, Simvastatin 10 mg	106	50.20	10.01	69	48.21	13.57		1.99	[-1.74; 5.72]	3.1%
Braamskamp 2015, Pitavastatin 1 mg 26 55.30 13.20 27 52.90 10.90 — 🟣 2.40 [-4.13; 8.93] 1.3%	Avis 2010, Rosuvastatin 20 mg	44	50.00	13.00	16	48.00	3.38		2.00	[-2.18; 6.18]	2.6%
	Braamskamp 2015, Pitavastatin 1 mg	26	55.30	13.20	27	52.90	10.90		2.40	[-4.13; 8.93]	1.3%
Clauss 2005, Lovastatin 40 mg 2.60 [-2.76; 7.96] 1.8%	Clauss 2005, Lovastatin 40 mg	35	49.80	11.20	19	47.20	8.60		2.60	[-2.76; 7.96]	1.8%
Stein 1999, Lovastatin 10 mg 63 46.80 1.02 61 44.00 1.02 10 2.80 [2.44; 3.16] 10.7%	Stein 1999, Lovastatin 10 mg	63	46.80	1.02	61	44.00	1.02	i i i i i i i i i i i i i i i i i i i	2.80	[2.44; 3.16]	10.7%
Stein 1999, Lovastatin 40 mg 63 47.25 1.02 59 44.44 1.04 2.81 [2.44; 3.18] 10.7%	Stein 1999, Lovastatin 40 mg	63	47.25	1.02	59	44.44	1.04	1 🖬	2.81	[2.44; 3.18]	10.7%
de Jongh 2002, Simvastatin 40 mg 20.99 [-1.18; 7.16] 2.6%	de Jongh 2002, Simvastatin 40 mg	106	50.30	10.09	69	47.31	15.70		2.99	[-1.18; 7.16]	2.6%
Knipscheer 1996, Pravastatin 5 mg 3.79 -6.36; 13.94] 0.6%	Knipscheer 1996, Pravastatin 5 mg	18	48.16	15.48	6	44.37	9.00		3.79	[-6.36; 13.94]	0.6%
Clauss 2005, Lovastatin 20 mg 4.60 -1.21; 10.41 1.5%	Clauss 2005, Lovastatin 20 mg	35	50.20	11.60	19	45.60	9.70		4.60	[-1.21; 10.41]	1.5%
Avis 2010, Rosuvastatin 10 mg 6.00 [2.33; 9.67] 3.2%	Avis 2010, Rosuvastatin 10 mg	44	54.00	11.00	15	48.00	3.38	! ∎	6.00	[2.33; 9.67]	3.2%
Knipscheer 1996, Pravastatin 20 mg 18 51.41 16.67 6 44.37 9.00	Knipscheer 1996, Pravastatin 20 mg	18	51.41	16.67	6	44.37	9.00		- 7.04	[-3.50; 17.58]	0.5%
Random effects model 1428 1053 🝦 1.52 [0.75; 2.30] 100%	Random effects model	1428			1053			•	1.52	[0.75; 2.30]	100%
Heterogeneity: I-squared = 93.5%, tau-squared = 1.426, p < 0.0001	Heterogeneity: I-squared = 93.5%, tau-squared = 1.426, p < 0.0001										
- TS - U - S U - S U - S								-10 -10 -0 15 10 5			

Appendix 4 – Forest plots showing the effect of statin therapy on high-density lipoprotein (HDL) cholesterol levels.

Appendix V

		sta	atins		pla	cebo	Mean difference			
Study	Total	Mean	SD	Total	Mean	SD	; 1	MD	95%-CI	W(random)
Stein 1999, Lovatatin 40 mg	63	107.54	5.01	59	188.94	5.01 💽		-81.40	[-83.18; -79.62]	6.6%
McCrindle 2003, Atorvastatin 10 mg–20 mg	140	121.70	2.20	47	195.10	6.10 💽		-73.40	[-75.18; -71.62]	6.6%
de Jongh 2002, Simvastatin 40 mg	106	118.55	35.34	69	181.27	43.28 -	F I	-62.72	[-74.95; -50.49]	6.2%
de Jongh 2002, Simvastatin 10 mg	106	128.09	36.77	69	187.60	42.71	-	-59.51	[-71.78; -47.24]	6.2%
de Jongh 2002, Simvastatin 20 mg	106	123.77	37.62	69	182.39	43.32		-58.62	[-71.10; -46.14]	6.2%
Avis 2010, Rosuvastatin 10 mg	44	90.00	30.00	15	140.00	10.15		-50.00	[-60.24; -39.76]	6.3%
Avis 2010, Rosuvastatin 20 mg	44	90.00	20.00	15	140.00	10.15	₩	-50.00	[-57.83; -42.17]	6.5%
Braamskamp 2015, Pitavastatin 4 mg	24	100.80	22.50	27	142.60	27.90		-41.80	[-55.65; -27.95]	6.1%
Avis 2010, Rosuvastatin 5 mg	42	100.00	20.00	16	140.00	9.60	A	-40.00	[-47.66; -32.34]	6.5%
Braamskamp 2015, Pitavastatin 2 mg	26	105.80	27.00	27	142.60	27.90	- -	-36.80	[-51.58; -22.02]	6.1%
Clauss 2005, Lovatatin 40 mg	35	141.10	37.90	19	176.30	31.60		-35.20	[-54.16; -16.24]	5.7%
Braamskamp 2015, Pitavastatin 1 mg	26	110.30	19.40	27	142.60	27.90		-32.30	[-45.20; -19.40]	6.2%
Clauss 2005, Lovastatin 20 mg	35	149.90	41.30	19	179.80	46.80		-29.90	[-55.00; -4.80]	5.2%
Rodenburg 2006, Pravastatin 40 mg	90	114.00	39.80	88	139.80	31.40		-25.80	[-36.32: -15.28]	6.3%
Van der Graaf 2008, Simvastatin 40 mg/Ezetimibe 10 mg	126	101.25	2.72	120	122.08	2.79		-20.83	[-21.52; -20.14]	6.6%
Van der Graaf 2008, Simvastatin 10 mg-20 mg-40 mg/Ezetimibe 10 mg	126	108.29	2.57	120	125.27	2.59		-16.98	[-17.63; -16.33]	6.6%
Random effects model	1139			806			│	-44.96	[-57.39; -32.53]	100%
Heterogeneity: I-squared = 99.8%, tau-squared = 607.2, p < 0.0001										
							-50 0 50			

Appendix 5 – Forest plots showing the effect of statin therapy on apolipoprotein B levels.

